Telmisartan is indicated for essential hypertension, risk reduction of cardiovascular disease. Reduce the risk of death from myocardial infarction, stroke and cardiovascular disease in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor (ACEI).

Rosuvastatin indicated in primary hypercholesterolemia (Type IIa including heterozygous familial hypercholesterolemia) and combined hyperlipidaemia (Type IIb), primary dysbetalipoproteinemia (Type III) and homozygous familial hypercholesterolemia.

Therapeutic Category: Lipid modifying agent combinations